Clinical Trial

Focal Versus Whole Gland High Dose-Rate Brachytherapy (HDR-BT) Boost to External Beam Radiotherapy in Localized Prostate Cancer: A Phase 2 Randomized Trial

Study acronym: FORWARD
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This project aims to compare the changes in the urinary quality of life (QoL) following focal high dose-rate brachytherapy (HDR-BT) boost to stereotactic ablative radiotherapy (SABR), compared to standard whole gland HDR-BT boost, in the treatment of men diagnosed with intermediate- and high-risk prostate cancer, with have an identifiable DIL on mpMRI.
Trial Details
NCT Number NCT07300566
Lead Sponsor Joelle Helou
Collaborators: London Health Sciences Centre
Conditions Prostate Cancer
Enrollment 58 participants
Start Date 2026-02
Primary Completion 2031-03 (estimated)
Study Completion 2033-03 (estimated)
Updated on ClinicalTrials.gov 2025-12-24